SCHEMBL24252316

SCHEMBL24252316

COc1ccc(CNc2nc(C)cc3cc(-c4cccc(B5OC(C)(C)C(C)(C)O5)c4)ccc23)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 20/20 0.47
CYP3A4 P08684 20/20 0.47
CYP2C19 P33261 19/20 0.47
CYP2D6 P10635 16/20 0.47
CYP2C9 P11712 16/20 0.47
TSHR P16473 14/20 0.47
HSD17B10 Q99714 12/20 0.47
USP2 O75604 10/20 0.47
CLK4 Q9HAZ1 10/20 0.47
ALDH1A1 P00352 10/20 0.47
MEN1 O00255 8/20 0.47
KMT2A Q03164 8/20 0.47
ALOX15 P16050 4/20 0.47
LMNA P02545 11/20 0.45
MAPK1 P28482 5/20 0.44
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.43
TP53 P04637 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30467588 1.00 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL24252399 0.89 CYP1A2 (0.43) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL30467648 0.89 CYP1A2 (0.43) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL30467781 0.88 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL24252769 0.88 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL24252756 0.82 CYP1A2 (0.53) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL30467576 0.82 CYP1A2 (0.53) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL30467577 0.82 CYP1A2 (0.53) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL30467808 0.81 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL29015421 0.81 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH CYP1A2 4150/4885CYP3A4 4043/4885CYP2C19 3592/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 CYP1A2 3838/4885CYP3A4 3719/4885CYP2C19 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.